abstract |
The disclosure relates generally to gamma polyglutamated raltitrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated raltitrexed, and methods of making and using the gamma polyglutamated raltitrexed compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). |